First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Laboratorios Farmaceuticos Rovi: the story is balanced — CDMO contract announcements and renewals, particularly for high-value biologics or complex injectables that utilize…
★ Analysts see FY2027 revenue reaching $891M — +15.6% growth in a single year.
What Moves the Stock
1CDMO contract announcements and renewals, particularly for high-value biologics or complex injectables that utilize Granada manufacturing capacity
2Post-COVID revenue normalization trajectory as Moderna vaccine manufacturing winds down and the company transitions capacity to other products
3ISM platform partnership developments and regulatory approvals for long-acting injectable formulations using Rovi's proprietary technology
4Bemiparin sales trends in Spain and international market expansion, particularly in emerging markets where LMWH adoption is growing
5European pharmaceutical sector M&A activity and potential strategic interest in specialty CDMO assets
6Contract Development & Manufacturing (CDMO) services - historically 50-60% of revenue, including Moderna COVID-19 vaccine fill-finish operations which peaked in 2021-2022
7Proprietary pharmaceutical products - approximately 40-50%, primarily Bemiparin (LMWH anticoagulant) sold in Spain and international markets
8ISM platform licensing and partnerships for long-acting injectable formulations of third-party molecules
growth - The 5.6x price-to-sales and 21.7x EV/EBITDA multiples reflect investor expectations for recovery and growth as the company…
Rising interest rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples…
Watch on earnings: Quarterly CDMO revenue excluding Moderna to track underlying business momentum and new contract wins, Granada facility capacity utilization and announced production schedules for 2026-2027, ISM platform partnership announcements and milestone payments from licensing agreements.
One Sentence Summary:
Laboratorios Farmaceuticos Rovi: the story is balanced — cdmo contract announcements and renewals, particularly for high-value biologics or complex injectables that utilize granada manufacturing.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.